Search hospitals > Maryland > Bethesda
American Oncology Partners of Maryland, PA
Claim this profileBethesda, Maryland 20817
Global Leader in Lymphoma
Global Leader in Chronic Lymphocytic Leukemia
Conducts research for Lung Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Lymphoid Hematopoietic Disease
48 reported clinical trials
4 medical researchers
Summary
American Oncology Partners of Maryland, PA is a medical facility located in Bethesda, Maryland. This center is recognized for care of Lymphoma, Chronic Lymphocytic Leukemia, Lung Cancer, Adult T-Cell Leukemia/Lymphoma, Lymphoid Hematopoietic Disease and other specialties. American Oncology Partners of Maryland, PA is involved with conducting 48 clinical trials across 82 conditions. There are 4 research doctors associated with this hospital, such as Mark Goldstein, MD, Ralph Boccia, Bruce D Cheson, and Ralph Vincent Boccia.Area of expertise
1Lymphoma
Global LeaderCD20 positive
MYC positive
Stage II
2Chronic Lymphocytic Leukemia
Global LeaderTop PIs
Mark Goldstein, MDJEM Research Institute4 years of reported clinical research
Expert in Alzheimer's Disease
Studies Colorectal Cancer
29 reported clinical trials
46 drugs studied
Ralph BocciaAmerican Oncology Partners of Maryland, PA12 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
16 reported clinical trials
32 drugs studied
Bruce D ChesonAmerican Oncology Partners of Maryland, PA3 years of reported clinical research
Studies Lymphoma
Studies Adult T-Cell Leukemia/Lymphoma
5 reported clinical trials
5 drugs studied
Ralph Vincent BocciaAmerican Oncology Partners of Maryland, PA4 years of reported clinical research
Studies Myelodysplastic syndrome
Studies Myelodysplastic Syndrome
1 reported clinical trial
2 drugs studied
Clinical Trials running at American Oncology Partners of Maryland, PA
Chronic Lymphocytic Leukemia
Lung Cancer
Myelofibrosis
Lymphoma
Breast Cancer
Small Cell Lung Cancer
Follicular Lymphoma
Adult T-Cell Leukemia/Lymphoma
Lymphoid Hematopoietic Disease
Non-Small Cell Lung Cancer
BGB-16673
for Chronic Lymphocytic Leukemia
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Recruiting2 awards Phase 34 criteria
Venetoclax + Obinutuzumab/Acalabrutinib
for Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of CLL. Study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 120 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. Participants in Arm A will receive oral venetoclax in combination with IV infused obinutuzumab, with a 5 week venetoclax ramp up. Participants in Arm B will receive oral venetoclax in combination with oral acalabrutinib, with a 5 week venetoclax ramp up. Participants in Arm C and Arm D will receive oral venetoclax in combination with oral acalabrutinib, with differing venetoclax ramp up periods. The total study duration is approximately 28 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting2 awards Phase 33 criteria
Venetoclax + cBTKi
for Chronic Lymphocytic Leukemia
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Recruiting1 award Phase 22 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at American Oncology Partners of Maryland, PA?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.